2023-08-05 04:01:09
The Food and Drug Administration (FDA) on Friday approved the oral pill from Biogen and Sage Therapeutics to treat postpartum depression (PPD) in adults.
The companies had asked the FDA to approve the drug, Zurzuvae, to treat major depressive disorder, or clinical depression, as well as postpartum depression, which affects millions of people.
PPD severely affects a woman’s ability to regain normal functioning, while potentially affecting the mother’s relationship with her child.
Analysts expected shares of both companies to fall if the drug was only approved for postpartum depression, due to the smaller patient population.
Until now, according to the FDA, treatment for postpartum depression was only available as an intravenous injection.
In 2021, an estimated 21 million adults in the United States have experienced at least one episode of major depressive disorder, which is characterized by a persistent feeling of sadness. Postpartum depression (PPD) affects approximately one in seven women who give birth.
1691210735
#FDA #approves #BiogenSage #Therapeutics #pill #postpartum #depression
